Bluejay Diagnostics Reaches Key Enrollment Milestone in SYMON-II Pivotal Sepsis Trial

Key Developments

• Bluejay Diagnostics, Inc. has successfully enrolled 624 patients in the ongoing SYMON-II pivotal clinical trial, which is evaluating the company’s Symphony™ IL-6 test platform for use in critical care settings.
• The pivotal trial aims for a target enrollment of 750 patients, with completion expected in the next 2 to 3 months depending on site activity and patient flow.
• The trial’s inclusion and exclusion criteria have not excluded a significant number of patients, indicating strong patient recruitment and efficient site execution.
• The Symphony™ IL-6 test is designed for rapid, near-patient results to help clinicians assess patient severity and guide timely decisions in acute and critical care environments, particularly for sepsis triage and monitoring.
• The company plans to use the SYMON-II study results to support a 510(k) regulatory submission to the U.S. FDA.

Details and Strategic Implications

Bluejay’s CEO, Neil Dey, highlighted that reaching 624 enrolled patients in the SYMON-II trial is a significant milestone, reflecting the strong execution by the company’s clinical team and ongoing commitment from investigators and partners. This positions Bluejay to complete trial enrollment soon and to deliver clinical insights that have the potential to improve outcomes in critical care settings.

The SYMON-II study is part of Bluejay’s broader SYMON Clinical Study Program, which also includes:

• SYMON-I (NCT06181604): A pilot study to determine IL-6 levels associated with key outcomes such as 28-day all-cause mortality and in-hospital mortality.
• SYMON-III (NCT07425587): A pilot study focused on IL-6 levels in patients with increasing severity of infection in the emergency department and risk of developing sepsis.

The Symphony™ IL-6 Test, Bluejay’s lead product candidate, is designed to produce accurate, reliable results in about 20 minutes from ‘sample-to-result’. This rapid turnaround aims to empower medical professionals to make earlier and more effective triage and treatment decisions for sepsis, a condition with high mortality and significant clinical urgency.

It is important to note that the Symphony system is currently an investigational device and does not yet have regulatory clearance. Bluejay must obtain authorization from the U.S. Food and Drug Administration (FDA) before the product can be marketed in the United States.

Why This Matters to Shareholders

• Near-Term Catalysts: Completion of SYMON-II enrollment and subsequent data readout are potential near-term catalysts that could impact Bluejay’s share price.
• Regulatory Milestone: The SYMON-II trial is intended to support a 510(k) submission to the FDA. Positive trial results and regulatory progress would be highly significant for Bluejay’s commercial prospects.
• Market Opportunity: Rapid diagnostic tools for sepsis represent a large and growing market. If cleared, Symphony could address a critical unmet need in emergency and critical care settings.
• Risk Factors: As with all clinical-stage companies, Bluejay’s future value is closely tied to successful trial completion, positive data, and regulatory approval. Any delays, negative results, or regulatory setbacks could materially affect the share price.

Forward-Looking Statements

The company cautions that actual results may differ materially from forward-looking statements due to known and unknown risks, including those detailed in its recent SEC filings. Investors should not put undue reliance on projections, as future events may diverge from current expectations.

Investor Contact

Neil Dey
Bluejay Diagnostics, Inc.
Email: [email protected]
Phone: 978-631-0310
www.bluejaydx.com

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors are urged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information herein is based on a company press release dated April 7, 2026, and may be subject to change or update.

View Bluejay Diagnostics, Inc. Historical chart here